New obesity drug combo tested in major safety trial
NCT ID NCT06771115
Summary
This study tested if a new drug called VTX3232 is safe and well-tolerated when taken alone or combined with the established weight-loss medication semaglutide. About 176 adults with obesity received either the new drug, a placebo, or combinations of these for 12 weeks. The main goal was to check for side effects and see how the body processes the drug, while also measuring changes in a marker of inflammation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
840001
Largo, Florida, 33761, United States
-
840002
Austin, Texas, 78705, United States
-
840003
Lake Forest, California, 92630, United States
-
840005
Birmingham, Alabama, 35235, United States
-
840006
Dallas, Texas, 75230, United States
-
840010
Waco, Texas, 76710, United States
-
840011
Long Beach, California, 90815, United States
-
840012
Ocoee, Florida, 34761, United States
-
840013
San Antonio, Texas, 78229, United States
-
840014
Newton, Kansas, 67114, United States
-
840015
Marrero, Louisiana, 70072, United States
-
840016
Port Orange, Florida, 32127, United States
-
840017
Marrero, Louisiana, 70072, United States
-
840018
San Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.